Novavax Inc

Financials

Cash from operating activities -42.54 M322.95 M-415.94 M-713.97 M-87.26 M-244.63 M -244.63 M Cash from investing activities -377.78 M100.15 M-92.98 M-58.81 M-204.04 M-78.27 M -78.27 M Cash from financing activities 984.76 M461.71 M324.99 M4.47 M260.58 M27.74 M 27.74 M Free cash flow -97.16 M265.46 M-508.92 M-772.77 M-101.9 M-251.02 M -251.02 M

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

NVAX

Financials

Novavax Inc

News

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Routine Vaccines Okay For Now: Investment Implications Of The Court Decision (XLV)

Jefferies reiterates Buy on Novavax stock, cites adjuvant platform

Novavax at Leerink Global Healthcare Conference: Strategic Shift in Focus

Novavax at TD Cowen Conference: Strategic Shift to Adjuvant Licensing

Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?

Novavax, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:NVAX) 2026-02-28

Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof (NASDAQ:NVAX)

What's Going On With Novavax Stock On Friday? - Novavax (NASDAQ:NVAX)